Stem Cell Reports (Jul 2016)

Dopamine D2 Receptor-Mediated Regulation of Pancreatic β Cell Mass

  • Daisuke Sakano,
  • Sungik Choi,
  • Masateru Kataoka,
  • Nobuaki Shiraki,
  • Motonari Uesugi,
  • Kazuhiko Kume,
  • Shoen Kume

DOI
https://doi.org/10.1016/j.stemcr.2016.05.015
Journal volume & issue
Vol. 7, no. 1
pp. 95 – 109

Abstract

Read online

Understanding the molecular mechanisms that regulate β cell mass and proliferation is important for the treatment of diabetes. Here, we identified domperidone (DPD), a dopamine D2 receptor (DRD2) antagonist that enhances β cell mass. Over time, islet β cell loss occurs in dissociation cultures, and this was inhibited by DPD. DPD increased proliferation and decreased apoptosis of β cells through increasing intracellular cAMP. DPD prevented β cell dedifferentiation, which together highly contributed to the increased β cell mass. DRD2 knockdown phenocopied the effects of domperidone and increased the number of β cells. Drd2 overexpression sensitized the dopamine responsiveness of β cells and increased apoptosis. Further analysis revealed that the adenosine agonist 5′-N-ethylcarboxamidoadenosine, a previously identified promoter of β cell proliferation, acted with DPD to increase the number of β cells. In humans, dopamine also modulates β cell mass through DRD2 and exerts an inhibitory effect on adenosine signaling.

Keywords